Loading
NASDAQHealthcareBiotechnology
Latest quote
$13.98
−$0.76 · -5.16%
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Latest quote
$13.98
−$0.76 · -5.16%
After-hours
$13.50
−$0.48 · -3.43%
Sep 10, 7:58 PM ET
Regular session · ET · Market data may be delayed.
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Day range
Current $13.98
52-week range
Current $13.98
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
43
Mixed
Risk
80
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Day range
Current $13.98
52-week range
Current $13.98
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 67.22M USD | 138.39M USD | 157.75M USD | 205.76M USD | 12.36M USD |
| Cost of goods sold | 3.03M USD | — | — | — | — |
| Gross profit | 64.2M USD | 138.39M USD | 157.75M USD | 205.76M USD | 12.36M USD |
| Research and development | 112.21M USD | 195.16M USD | 192.13M USD | 147.75M USD | 173.76M USD |
| Selling, general, and administrative | 46.08M USD | 52.82M USD | 52.87M USD | 46.07M USD | 41.45M USD |
| Operating expenses | 139.15M USD | 234.06M USD | 235.95M USD | 193.58M USD | 215.21M USD |
| Interest income | 10.1M USD | 15.2M USD | 17.36M USD | 2.58M USD | 753K USD |
| Interest expense | — | — | 767K USD | 3M USD | 2.67M USD |
| Depreciation and amortization | 3.03M USD | 3.54M USD | 2.96M USD | 1.53M USD | 1.19M USD |
| Operating income | −74.96M USD | −95.67M USD | −78.21M USD | 12.18M USD | −202.85M USD |
| Net income | −65.78M USD | −80.94M USD | −29.73M USD | 9.35M USD | −203.67M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$41.00
193.28% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jan 8, 2013 | $0.0085Special | Jan 8, 2013 | Jan 15, 2013 |
Dividend | Jan 4, 2013 | $0.0085Monthly | Jan 8, 2013 | Jan 15, 2013 |
Dividend | Dec 5, 2012 | $0.0086Monthly | — | Dec 15, 2012 |
Dividend | Nov 6, 2012 | $0.0086Monthly | — | Nov 15, 2012 |
Dividend | Oct 3, 2012 | $0.0086Monthly | — | Oct 15, 2012 |
Dividend | Sep 5, 2012 | $0.0086Monthly | — | Sep 15, 2012 |
Ex-dividend Jan 8, 2013
$0.0085
Special
Record Jan 8, 2013 · Payment Jan 15, 2013
Ex-dividend Jan 4, 2013
$0.0085
Monthly
Record Jan 8, 2013 · Payment Jan 15, 2013
Ex-dividend Dec 5, 2012
$0.0086
Monthly
Payment Dec 15, 2012
Ex-dividend Nov 6, 2012
$0.0086
Monthly
Payment Nov 15, 2012
Ex-dividend Oct 3, 2012
$0.0086
Monthly
Payment Oct 15, 2012
Ex-dividend Sep 5, 2012
$0.0086
Monthly
Payment Sep 15, 2012
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG44.49M2.27%1.56B USD0.75%$45.38-2.00%
iShares Russell 2000 ETFIWM10.25M0.01%80.51B USD0.19%$287.7-1.01%
Vanguard Morningstar Total Stock Market ETFVTI4.59M0.00%2.3T USD0.03%$373.24-0.62%
iShares Russell 2000 Value ETFIWN3.72M0.03%14.61B USD0.24%$218.97-0.68%
iShares Biotechnology ETFIBB2.98M0.03%10.73B USD0.44%$202.64-1.39%
Schwab U.S. Small-Cap ETFSCHA1.92M0.01%22.62B USD0.03%$33.65-1.32%
Vanguard Extended Market ETFVXF1.69M0.00%93.7B USD0.05%$236.16-1.05%
Invesco RAFI US 1500 Small-Mid ETFPRFZ1.36M0.05%2.76B USD0.36%$53.2519-1.00%ARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Extended Market ETFVXFInvesco RAFI US 1500 Small-Mid ETFPRFZAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
